ZEALAND PHARMA A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 661.2 DKK | +1.73% |
|
+0.69% | +76.31% |
| Sales 2024 * | 441M 63.56M | Sales 2025 * | 1.02B 147M | Capitalization | 40.49B 5.84B |
|---|---|---|---|---|---|
| Net income 2024 * | -653M -94.16M | Net income 2025 * | -399M -57.53M | EV / Sales 2024 * | 86.5 x |
| Net cash position 2024 * | 2.37B 341M | Net cash position 2025 * | 2.44B 352M | EV / Sales 2025 * | 37.4 x |
| P/E ratio 2024 * |
-65
x | P/E ratio 2025 * |
-68.4
x | Employees | 270 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | +2.12% | ||
| 1 week | +2.37% | ||
| Current month | +4.61% | ||
| 1 month | +8.16% | ||
| 3 months | -2.48% | ||
| 6 months | +96.42% | ||
| Current year | +79.26% |
1 week
602.50
681.00
1 month
560.00681.00
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 775 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 659 | +1.38% | 156 528 |
| 24-06-07 | 650 | -0.15% | 547,373 |
| 24-06-06 | 651 | +6.63% | 527,014 |
| 24-06-04 | 610.5 | -6.58% | 497,532 |
| 24-06-03 | 653.5 | +2.19% | 247,885 |
Delayed Quote Nasdaq Copenhagen, June 10, 2024 at 05:14 am EDT
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
650
DKK
Average target price
790.9
DKK
Spread / Average Target
+21.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +79.26% | 5.87B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +1.46% | 22.78B | |
| -11.14% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- ZEAL Stock
